Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Method Validation in Pharma in 2026: GMP Inspection View

GMP inspections increasingly highlight gaps in pharmaceutical analytical validation. This article explains how regulators evaluate validation documentation, acceptance criteria, and lifecycle management, and why weaknesses in analytical method performance often escalate into formal inspection findings.
  • Blog, GMP, Validation and Qualification
GMP inspection findings caused by pharmaceutical analytical validation weaknesses, showing issues with validation documentation, acceptance criteria, and analytical method performance in regulated laboratories.

Pharma Validation as a Strategic Compliance System in 2026

This article examines pharmaceutical validation as a governance-driven compliance system, exploring lifecycle validation management, regulatory expectations, and inspection readiness. It offers strategic insight into how validation maturity, data integrity, and oversight architecture shape regulatory confidence across pharmaceutical quality systems.
  • Blog, GMP, Validation and Qualification
Pharmaceutical compliance architecture illustrating lifecycle validation management, regulatory oversight, and inspection readiness within GMP environments

RMP in Pharmacovigilance in 2026: Regulatory Findings

This article explains how a pharmacovigilance risk management plan supports inspection readiness. It explores EU RMP pharmacovigilance expectations, RMP effectivenes evaluation, additional risk minimisation measures, and common pharmacovigilance inspection findings linked to weak RMP lifecycle management.
  • Blog, GMP, Quality Management System
Drug safety risk management plan illustrating EMA RMP requirements, effectiveness evaluation, and lifecycle management during pharmacovigilance inspections

Signal Detection in Pharmacovigilance in 2026: Inspection Findings

Pharmacovigilance inspections increasingly identify gaps in signal management processes. This article explains how safety signal detection failures lead to inspection findings and outlines regulatory expectations, surveillance system requirements, and practical approaches to improve inspection readiness.
  • Blog, GMP, Quality Management System
Pharmacovigilance inspection scenario showing safety signal detection process, regulatory review of drug safety data, and weaknesses in pharmacovigilance surveillance systems identified during inspections.

Shelf Life Determination in 2026: GMP Stability Focus

This article explains how stability studies GMP support shelf life justification during inspections. It examines pharmaceutical stability testing, ongoing stability programs, and common GMP inspection observations when expiration date assignment lacks scientific or regulatory support.
  • Blog, GMP, Quality Management System
GMP stability requirements illustrated through pharmaceutical stability testing, ongoing stability program review, and regulatory evaluation of expiry decisions

Good Manufacturing Practices History in 2026: How GMP Evolved Under Inspection Pressure

GMP did not emerge by chance. This article traces the history of GMP regulations, key enforcement milestones, and regulatory inspection evolution that shaped modern pharmaceutical manufacturing standards and quality systems still used to assess compliance today.
  • Blog, GMP, Quality Management System
Conceptual image illustrating the GMP evolution timeline, linking FDA GMP history, WHO GMP background, and regulatory inspection evolution to modern pharmaceutical manufacturing standards.

Vendor Audit Checklist in 2026: GMP Inspection Focus

GMP inspections increasingly focus on supplier oversight and audit execution. This article explains how vendor audit programs, supplier qualification, and risk-based evaluation influence inspection outcomes and how inspection-ready audit checklists strengthen GMP supplier control systems.
  • Blog, GMP, Quality Management System
Inspector reviewing supplier audit checklist to assess GMP vendor audit requirements, supplier compliance, and effectiveness of the vendor qualification process within a GMP supplier control system.

Pharmaceutical Documentation in 2026: GMP Inspection Focus

GMP inspections increasingly rely on documentation quality to judge system control. This article explains how regulators assess GMP records, data integrity, and traceability, and how inspection-ready documentation systems reduce audit findings and escalation risk.
  • Blog, GMP, Quality Management System
Inspector reviewing GMP documentation and deviation records to assess data integrity, ALCOA plus documentation principles, and traceability in GMP records during inspection readiness evaluation.

Adverse Drug Reactions Explained Across the Pharmacovigilance Lifecycle in 2026

Explore how adverse drug reactions evolve across the pharmacovigilance lifecycle, highlighting post-marketing safety, inspection-sensitive gaps, and structured workflows that ensure regulatory compliance, traceable oversight, and proactive risk management for pharmaceutical teams.
  • Blog, GMP, Quality Management System
Pharmacovigilance workflow showing clinical safety monitoring, post marketing adverse drug reactions, signal detection, and ADR reporting requirements for effective pharmacovigilance adverse events management

Pharmacovigilance Phases Explained Across the Product Lifecycle in 2026

A practical overview of the pharmacovigilance lifecycle, explaining how clinical safety monitoring, signal detection, and risk management planning evolve from pre-marketing activities to post-marketing oversight under current GVP compliance and regulatory inspection expectations.
  • Blog, GMP, GxP, Quality Management System
Illustration of pharmacovigilance process including signal detection, risk management plan, and GVP compliance across product lifecycle